Drug
Evinacumab clinical trials
Also written REGN1500 and Evkeeza™.
- studies test it
- 11
- open now
- 0
- in phase 3
- 4
- first study started
- 2012
How studies write it
Studies that test it under each name
Studies by the year they started
11 studies that test it; most in 2018 (3)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2017 | 2 |
| 2018 | 3 |
| 2020 | 1 |
| 2021 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 4
- Phase 3
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 1
Regeneron Pharmaceuticals (10) · Daniel Gaudet (1)
Studies
Open first, then newest update. How each study uses evinacumab is read from its arms, and is right about nine times in ten.
Testing it · 11
- Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial HypercholesterolemiaCompletedPhase 3Regeneron PharmaceuticalsNCT03409744Written as evinacumab
- Safety and Effectiveness of Evinacumab for the Treatment of Homozygous Familial HypercholesterolemiaCompletedPhase 3Daniel GaudetNCT05611528Written as Evinacumab
- Evaluate the Efficacy and Safety of Evinacumab in Pediatric Patients With Homozygous Familial HypercholesterolemiaCompletedPhase 3Regeneron PharmaceuticalsNCT04233918Written as Evinacumab
- Efficacy and Safety of Evinacumab in Adult Patients With Severe Hypertriglyceridemia for the Prevention of Recurrent Acute PancreatitisTerminatedPhase 2Regeneron PharmaceuticalsNCT04863014Written as evinacumab
- Safety and Efficacy Following Repeat-Dose of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute PancreatitisCompletedPhase 2Regeneron PharmaceuticalsNCT03452228Written as evinacumab
- Study of Evinacumab (REGN1500) in Participants With Persistent HypercholesterolemiaCompletedPhase 2Regeneron PharmaceuticalsNCT03175367Written as Evinacumab
- Efficacy and Safety of Evinacumab in Patients With Homozygous Familial HypercholesterolemiaCompletedPhase 3Regeneron PharmaceuticalsNCT03399786Written as evinacumab
- Study of REGN1500 in Participants With Homozygous Familial Hypercholesterolemia (HoFH)CompletedPhase 2Regeneron PharmaceuticalsNCT02265952Written as REGN1500 250 mg SC/15 mg/kg IV/450 mg SC
- Study of Evinacumab (REGN1500) in Caucasian and in Japanese Healthy VolunteersCompletedPhase 1Regeneron PharmaceuticalsNCT03146416Written as Evinacumab
- Study to Assess the Safety and Tolerability of Single Doses of REGN1500CompletedPhase 1Regeneron PharmaceuticalsNCT01749878Written as REGN1500
- Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1500CompletedPhase 1Regeneron PharmaceuticalsNCT02107872Written as REGN1500
Given in every arm · 1 — evinacumab is usual care beside what is tested
Codes
What other systems call evinacumab · ClinicalTrials.gg INT000744
- MeSH (NLM) C000621590evinacumabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) T8B2ORP1DWEVINACUMABConfirmed FDA, NLM, Wikidata
- RxNorm 2478335One source FDA
- Wikidata Q19904115evinacumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C169973EvinacumabOne source FDA
- DrugBank DB15354One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000621590 | evinacumab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | T8B2ORP1DW | EVINACUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2478335 | — | One source FDA |
| Wikidata | Q19904115 | evinacumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C169973 | Evinacumab | One source FDA |
| DrugBank | DB15354 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.